Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - tolkapon - parkinsonova bolest - anti-parkinsonove bolesti lijekovima, drugim дофаминергических posrednika - tasmar je indiciran u kombinaciji s levodopom / benserazide ili levodope / carbidopa bolesnicima s levodope reagira idiopatske parkinsonove bolesti i motoričke fluktuacije, koji nisu ili se ne podnose druge catechol-o-methyltransferase (comt) inhibitori. zbog rizika od potencijalno smrtonosne, akutnog oštećenja jetre, tasmar ne treba shvatiti kao prizemlju, kuhinju, blagovaonu-linija terapije za леводопы / бенсеразида ili леводопы / карбидопы. s tasmar treba koristiti samo u kombinaciji s lijekovima леводопы / бенсеразида i леводопы / карбидопы da se informacije o učinku tih lijekova леводопы i odnosi se na njihova istodobna primjena s tasmar.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris limited, damastown industrial park, mulhuddart, dublin, irska - lantan karbonat - tableta za žvakanje - 1000 mg - urbroj: jedna tableta za žvakanje od 1000 mg sadrži količinu lantan karbonat oktahidrata ekvivalentnu 1000 mg lantana

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris limited, damastown industrial park, mulhuddart, dublin, irska - lantan karbonat - tableta za žvakanje - 500 mg - urbroj: jedna tableta za žvakanje od 500 mg sadrži količinu lantan karbonat oktahidrata ekvivalentnu 500 mg lantana

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris limited, damastown industrial park, mulhuddart, dublin, irska - lantan karbonat - tableta za žvakanje - 750 mg - urbroj: jedna tableta za žvakanje od 750 mg sadrži količinu lantan karbonat oktahidrata ekvivalentnu 750 mg lantana

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris healthcare limited, damastown industrial park, mulhuddart, dublin, irska - azelastinklorid - sprej za nos, otopina - urbroj: 1 ml otopine sadrži 1,5 mg azelastinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris limited, damastown industrial park, mulhuddart, dublin, irska - vankomicinklorid - prašak za otopinu za infuziju - urbroj: svaka bočica sadrži 1000 mg vankomicina (u obliku klorida), što odgovara 1 000 000 iu

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris limited, damastown industrial park, mulhuddart, dublin, irska - vankomicinklorid - prašak za otopinu za infuziju - urbroj: svaka bočica sadrži 500 mg vankomicina (u obliku klorida), što odgovara 500 000 iu

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.